#1 |
[mh "Atrial Fibrillation"] OR "atrial fibrillation":ab,ti OR [mh "Atrial Flutter"] OR "atrial flutter":ab,ti |
#2 |
[mh ^"Cerebrovascular Disorders"[mj]] or [mh Stroke] or [mh Thromboembolism] or [mh ^emorrhage] or [mh "Intracranial Hemorrhages"] or [mh "Brain Ischemia"] or [mh "Prothrombin Time"] or stroke:ab,ti or strokes:ab,ti or thromboembolism:ab,ti or thromboembolisms:ab,ti or thromboembolic:ab,ti or thromboses:ab,ti or hemorrhage:ab,ti or hemorrhages:ab,ti or hemorrhaging:ab,ti or hemorrhagic:ab,ti or haemorrhage:ab,ti or haemorrhages:ab,ti or haemorrhaging:ab,ti or haemorrhagic:ab,ti or ((bleeding or bleed or bleeds) near/2 (major or risk or event)):ab,ti or ((systemic or paradoxical or crossed) next/2 (embolism or embolisms)):ab,ti or ((brain or cerebral or brainstem or 'brain stem') next/2 (ischemia or ischaemia or ischemias or ischaemias or infarction or infarctions)):ab,ti or (transient next/2 (ischemic or ischaemic or ischaemia or ischemia) next/2 (attack or attacks)):ab,ti or TIA:ab,ti or TIAs:ab,ti or "cerebrovascular accident":ab,ti or "cerebrovascular accidents":ab,ti or CVA:ab,ti or CVAs:ab,ti or "brain vascular accident":ab,ti or "brain vascular accidents":ab,ti |
#3 |
[mh Risk] or risk:ab,ti or risks:ab,ti or [mh Safety] or safety:ab,ti or safe:ab,ti or [mh Incidence] or efficacy:ab,ti or efficacious:ab,ti or [mh /PC] or prevent:ab,ti or prevents:ab,ti or preventing:ab,ti or prevention:ab,ti or [mh "Treatment Outcome"] or [mh /AE] or (side next/1 effect*):ab,ti or (adverse next/3 (interaction* or response* or effect* or event* or reaction* or outcome*)):ab,ti or (unintended next/3 (interaction* or response* or effect* or event* or reaction* or outcome*)):ab,ti or (unintentional next/3 (interaction* or response* or effect* or event* or reaction* or outcome*)):ab,ti or (unwanted next/3 (interaction* or response* or effect* or event* or reaction* or outcome*)):ab,ti or (unexpected next/3 (interaction* or response* or effect* or event* or reaction* or outcome*)):ab,ti or (undesirable next/3 (interaction* or response* or effect* or event* or reaction* or outcome*)):ab,ti or "drug safety":ab,ti or "drug toxicity":ab,ti or tolerability:ab,ti or harm:ab,ti or harms:ab,ti or harmful:ab,ti or "treatment emergent":ab,ti or complication*:ab,ti or toxicity:ab,ti |
#4 |
{and #1-#3} |
#5 |
[mh Anticoagulants] or [mh Warfarin] or [mh Heparin] or [mh "Vitamin K"/AI] or [mh Rivaroxaban] or [mh Antithrombins] or [mh Dabigatran] or [mh "Blood Coagulation Factor Inhibitors"] or [mh "Factor Xa Inhibitors"] or warfarin:ab,ti or coumadin:ab,ti or "vitamin k":ab,ti or enoxaparin:ab,ti or lovenox:ab,ti or rivaroxaban:ab,ti or xarelto:ab,ti or dabigatran:ab,ti or pradaxa:ab,ti or heparin:ab,ti or apixaban:ab,ti or eliquis:ab,ti or edoxaban:ab,ti or lixiana:ab,ti or anticoagulant:ab,ti or anticoagulants:ab,ti or anticoagulation:ab,ti or "thrombin inhibitor":ab,ti or "thrombin inhibitors":ab,ti or antithrombin:ab,ti or antithrombins:ab,ti or antithrombotic:ab,ti or "factor Xa inhibitor":ab,ti or "factor Xa inhibitors":ab,ti or "Blood clotting inhibitor":ab,ti or "blood clotting inhibitors":ab,ti |
#6 |
[mh "Platelet Aggregation Inhibitors"] or [mh Aspirin] or [mh Dipyridamole] or clopidogrel:ab,ti or plavix:ab,ti or aspirin:ab,ti or dipyridamole:ab,ti or aggrenox:ab,ti or persantine:ab,ti or curantil:ab,ti or antiplatelet:ab,ti or anti-platelet:ab,ti or antiplatelets:ab,ti or anti-platelets:ab,ti or "platelet aggregation inhibitors":ab,ti or "platelet aggregation inhibitor":ab,ti or "platelet inhibitors":ab,ti or "platelet inhibitor":ab,ti or "platelet antagonists":ab,ti or "platelet antagonist":ab,ti |
#7 |
[mh "atrial appendage"/SU] or [mh "Septal Occluder Device"] or "atrial appendage":ab,ti or "atrial appendages":ab,ti or "atrium appendage":ab,ti or "auricular appendage":ab,ti or "auricular appendages":ab,ti or LAA:ab,ti or occluder:ab,ti or occluders:ab,ti or occlusion:ab,ti or AMPLATZER:ab,ti or AtriClip:ab,ti or PLAATO:ab,ti or Watchman:ab,ti or (atrial:ab,ti and modification:ab,ti) or lariat:ab,ti or atricure:ab,ti |
#8 |
#4 and {or #5-#7} |
#9 |
#8 Publication Year from 2011 |